Drug Resistance In DNA Repair Defective Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$122,032.00
Summary
Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and respond to new PARP inhibitor therapy, yet even then the cancer often recurs. I will use a new model to study human ovarian cancers in mice. My focus will be understanding resistance to PARP inhibitors in individual ovarian cancers and designing approaches to overcome this resistance.
Studies On New Mononuclear And Polynuclear Platinum Compounds With Trans-geometry
Funder
National Health and Medical Research Council
Funding Amount
$68,617.00
Summary
Even in post-genomic age cisplatin continues to be widely used as a highly successful anticancer drug. However, the drug has a number of side effects and does not show activity against many types of cancer. in some cases, resistant form of cancer develops for which the drug does not function. An example is ovarian cancer. This project aims to arrive at new platinum-based anticancer drugs targeted to ovarian cancer.